COGT Cogent Biosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why COGT matters now
Cogent Biosciences, Inc. (COGT) is a US stock in Healthcare. The latest InvestLog snapshot shows $40.51 with +1.35% on the session and $6.92B in market capitalization; recent performance reads 1-month +10.53% and YTD -2.76%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-97.4M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.9%.
The latest indexable market news headline is "Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $52.00; recent insider activity includes Ros Matthew filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.83
P/S
0.00
EV/EBITDA
-16.83
DCF Value
$0.74
FCF Yield
-4.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-83.3%
ROA
-39.2%
ROIC
-42.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-97.4M | $-0.60 |
| Q4 2025 | $0.00 | $-102.5M | $-1.13 |
| FY 2025 | $0.00 | $-328.9M | $-2.55 |
| Q3 2025 | $0.00 | $-80.9M | $-0.71 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$49.40
Target (Median)
$52.00
Target Range
$35.00 - $60.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.35
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.